¼¼°èÀÇ ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõ(ALS) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í Sanofi RilutekÀÌ ´ã´çÇÏ´Â ±âÃÊÀû ¿ªÇÒºÎÅÍ SOD1-ALS¿¡ ´ëÇÑ Biogen/IonisÀÇ QalsodyÀÇ À¯¸ÁÇÑ °¡´É¼º, FUS º¯ÀÌÇü ALS¿¡ ´ëÇÑ IonisÀÇ ulefnersen¸¦ µÑ·¯½Ñ ³«°ü·Ð±îÁö ALS Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â Àü·«Àû µ¿ÇâÀ» »ìÆìº¾´Ï´Ù. ¶ÇÇÑ ÁøÈÇÏ´Â ALS Ä¡·á Àü¸ÁÀ» »ó¼¼È÷ ºÐ¼®Çϰí, ALS Ä¡·áÀÇ Áøº¸¸¦ À§ÇÑ ÁÖ¿ä ±âȸ¿Í °úÁ¦¸¦ °Á¶ÇÕ´Ï´Ù.
¸ñÂ÷
°³¿ä
ÇöÀç ¹× ÇâÈÄ Ä¡·á ¾Ë°í¸®Áò
Á¶»ç ¸ñÀû
½ÂÀÎ ÀǾàǰ
- ±Û·çŸ¹Î»ê ¼ö¿ëü ÀÛ¿ëÁ¦
- Rilutek(riluzole; Sanofi)
- ÁöÁú °ú»êȹ° 15-HPETE ÀúÇØÁ¦
- Radicava(edaravone; Mitsubishi Tanabe Pharma)
- ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ¿ä¹ý
- Qalsody(tofersen; Biogen/Ionis)
ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦
- ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ¿ä¹ý
- Ulefnersen(ION363; Ionis)
- Ƽ·Î½ÅŰ³ª¾ÆÁ¦ ÀúÇØÁ¦
- ³ª³ë°áÁ¤ ±Ý
- CNM-Au8(Clene Nanomedicine)
- Áٱ⼼Æ÷ Ä¡·á
- Æ÷½ºÆ÷µð¿¡½ºÅ×¶óÁ¦ ÀúÇØÁ¦
- eIF2B Ȱ¼ºÈÀÎÀÚ
- DNL343(Denali Therapeutics)
- ½Ã±×¸¶ 1 ¼ö¿ëü ÀÛ¿ëÁ¦
- Pridopidine(Prilenia Therapeutics)
- ÀúºÐÀÚ·® ÀÌ´ç·ù
- Trehalose(SLS-005; Seelos Therapeutics)
- ciprofloxacin°ú celecoxibÀÇ °íÁ¤¿ë·® ¹èÇÕÁ¦
- PrimeC(NeuroSense Therapeutics)
- LINE-1 ¿ªÀü»ç È¿¼Ò ÀúÇØÁ¦
- Censavudine(TPN-101; Transposon Therapeutics)
- PIKfyve Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
- AIT-101(OrphAI Therapeutics)
- C1q ÀúÇØÁ¦
ÇâÈÄ Ä¡·á µ¿Çâ
ºÎ·Ï
KOL º¸°í¼
KSA
From the foundational role of Sanofi's Rilutek, the promising potential of Biogen/Ionis' Qalsody for SOD1-ALS, to the optimism surrounding Ionis' ulefnersen for FUS-mutated ALS, uncover the strategic trends shaping the future of ALS treatment. This report provides an in-depth analysis of the evolving therapeutic landscape, highlighting key opportunities and challenges in advancing ALS care. Explore the strategic implications for drug development, market dynamics, and patient care strategies.
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Approved drugs
- Glutamate receptor agonist
- Rilutek (riluzole; Sanofi)
- Lipoperoxide 15-HPETE inhibitor
- Radicava (edaravone; Mitsubishi Tanabe Pharma)
- Antisense oligonucleotide therapy
- Qalsody (tofersen; Biogen/Ionis)
Pipeline drugs
- Antisense oligonucleotide therapy
- Ulefnersen (ION363; Ionis)
- Tyrosine kinase inhibitor
- Nanocrystalline gold
- CNM-Au8 (Clene Nanomedicine)
- Stem cell therapy
- Phosphodiesterase inhibitor
- eIF2B activator
- DNL343 (Denali Therapeutics)
- Sigma-1 receptor agonist
- Pridopidine (Prilenia Therapeutics)
- Low molecular weight disaccharide
- Trehalose (SLS-005; Seelos Therapeutics)
- Fixed-dose combination of ciprofloxacin and celecoxib
- PrimeC (NeuroSense Therapeutics)
- LINE-1 reverse transcriptase inhibitor
- Censavudine (TPN-101; Transposon Therapeutics)
- PIKfyve kinase inhibitor
- AIT-101 (OrphAI Therapeutics)
- C1q inhibitor
Future treatment trends
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
KOL Bulletins